Studies performed with hydrofluoroalkane(HFA)-formoterol pressurised metered-dose inhaler (pMDI) extra-fine aerosol
| Asthma patients | First author [ref.] | Protocol | Primary outcome |
| Moderate to severe stable | Bousquet [147] | Single dose; n = 43 | Average FEV1 over 12 h |
| HFA-formoterol pMDI 12 μg | |||
| Formoterol DPI 12 μg | |||
| Placebo | |||
| Bousquet [148] | Single dose; n = 46 | Average FEV1 over 12 h | |
| HFA-formoterol pMDI 12 μg or 24 μg | |||
| Formoterol DPI 24 μg | |||
| Placebo | |||
| Molimard [149] | Cumulative doses; n = 22 | Safety | |
| HFA-formoterol pMDI | |||
| Formoterol DPI | |||
| Placebo | |||
| Langley [150] | Single dose; n = 38 | PD20 methacholine | |
| HFA-formoterol pMDI 12 μg | |||
| Formoterol DPI 12 μg | |||
| CFC-formoterol pMDI 12 μg | |||
| Placebo | |||
| Moderate to severe uncontrolled | Dusser [151] | Formoterol pMDI 12 or 24 μg; n = 227 | Morning peak flow |
| Formoterol DPI 12 or 24 μg; n = 221 | |||
| 3 months |
DPI: dry powder inhaler; FEV1: forced expiratory volume in 1 s; PD20: provocative dose causing a 20% fall in FEV1.